The U.S. Food and Drug Administration (FDA) has granted ETX101, an experimental gene therapy for Dravet syndrome, its…
Articles by Marisa Wexler, MS
A Phase 3 clinical trial testing the therapy candidate zorevunersen for Dravet syndrome is now recruiting children who still…
June is Dravet Syndrome Awareness Month in the U.S., and the Dravet Syndrome Foundation is spearheading efforts to raise…
Praxis Precision Medicines is gearing up to launch a clinical trial of its experimental anti-seizure therapy relutrigine in people…
Stoke Therapeutics and Biogen are teaming up for the further development and potential commercialization of zorevunersen,…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to relutrigine, a treatment candidate for…
Targeting a heart protein called NaV1.6 may help prevent sudden death in adults with Dravet syndrome, a study in…
The U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on higher doses of zorevunersen, an experimental…
Parents of children with Dravet syndrome in Spain say they don’t get enough support to help meet the emotional…
Although high-quality data are lacking, available evidence suggests that a procedure called vagus nerve stimulation (VNS) — which targets…